Abstract
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have